Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Nov 15, 2025; 16(11): 113005
Published online Nov 15, 2025. doi: 10.4239/wjd.v16.i11.113005
Published online Nov 15, 2025. doi: 10.4239/wjd.v16.i11.113005
Pharmacological management of major complications following left ventricular assist device implantation in type 2 diabetes mellitus
Ying-Lu Zhang, Wen-Yan Wang, Department of Cardiology, Institute of Cardiovascular Diseases, Heart Failure Center, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China
Zhen-Yu Liu, Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Co-corresponding authors: Wen-Yan Wang and Zhen-Yu Liu.
Author contributions: Wang WY was responsible for conceptualization; Liu ZY, Zhang YL, Wang WY were responsible for study design, data analysis, and data interpretation; Zhang YL and Liu ZY were responsible for writing - original draft preparation; Wang WY and Liu ZY were responsible for writing - review and editing; Wang WY and Liu ZY were responsible for supervision.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhen-Yu Liu, MD, Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Er Road, Shanghai 200025, China. liuzhenyu200210@sjtu.edu.cn
Received: August 13, 2025
Revised: September 7, 2025
Accepted: October 20, 2025
Published online: November 15, 2025
Processing time: 93 Days and 23.9 Hours
Revised: September 7, 2025
Accepted: October 20, 2025
Published online: November 15, 2025
Processing time: 93 Days and 23.9 Hours
Core Tip
Core Tip: Type 2 diabetes mellitus exacerbates left ventricular assist device (LVAD)-related complications via endothelial dysfunction and inflammation. This review highlights tailored strategies, including precision warfarin dosing, aspirin omission from magnetically levitated LVADs, SGLT-2 inhibitors/GLP-1 agonists for glycemic control, and novel infection/right ventricular failure management to optimize outcomes.